irinotecan has been researched along with Glioma in 118 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (6.78) | 18.2507 |
| 2000's | 51 (43.22) | 29.6817 |
| 2010's | 50 (42.37) | 24.3611 |
| 2020's | 9 (7.63) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, JW; Jung, HA; Kong, DS; Lee, JI; Lee, MS; Lee, SH; Lee, YP; Nam, DH; Seol, HJ | 1 |
| Andre, N; Beccaria, K; Bertozzi, AI; Boddaert, N; Bourdeaut, F; Butel, T; Cuinet, A; De Carli, E; de Marcellus, C; Dufour, C; Figarella-Branger, D; Fouyssac, F; Grill, J; Leblond, P; Pasqualini, C; Puget, S; Robert, MP; Tauziède-Espariat, A; Valteau-Couanet, D; Varlet, P | 1 |
| Biltekin, B; Cetin, A; Ozevren, H | 1 |
| Ballester, LY; Bhattacharjee, MB; Brown, RE; Buja, LM; Chen, L; Glass, WF; Hergenroeder, GW; Hunter, RL; Linendoll, N; Lu, G; Pilichowska, M; Pillai, AK; Rao, M; Tian, X; Wu, JK; Zhang, R; Zhu, JJ; Zhu, P | 1 |
| Hu, Y; Lu, J; Luo, P; Qian, R; Yang, X; Zhang, Y | 1 |
| Golby, AJ; McDannold, N; Power, C; Reardon, DA; Sun, T; Supko, JG; Vykhodtseva, N; Zhang, Y | 1 |
| Browd, SR; Cole, BL; Crotty, EE; Ellenbogen, RG; Ermoian, RP; Geyer, JR; Hauptman, JS; Leary, SES; Lee, A; Lockwood, CM; Millard, NE; Ojemann, JG; Olson, JM; Paulson, VA; Sato, AA; Vitanza, NA | 1 |
| André, N; Appay, R; Gentet, JC; Padovani, L; Revon-Rivière, G; Roux, C; Saultier, P; Scavarda, D; Verschuur, A | 1 |
| Cabrales, P; Oronsky, B; Reid, T | 1 |
| Chi, SN; Cohen, KJ; DiRenzo, J; Donson, AM; Dunkel, IJ; Etzl, MM; Foreman, NK; Gore, L; Kieran, MW; Kuei, MC; MacDonald, TJ; Macy, ME; Narendran, A; Ostrovnaya, I; Smith, AA; Trippett, TM | 1 |
| Jiang, X; Li, C; Liang, L; Liu, L; Lu, P; Qiao, Y; Wang, L; Xia, Y; Yang, T | 1 |
| Broholm, H; Christensen, IJ; Grunnet, K; Kosteljanetz, M; Larsen, VA; Lassen, U; Lukram, B; Michaelsen, SR; Poulsen, HS; Toft, A; Urup, T | 1 |
| Cloughesy, TF; Lee, EQ; McFaline-Figueroa, JR; Wen, PY | 1 |
| Cai, J; Chen, Q; Dong, J; Jiang, C; Li, S; Meng, X; Shi, L | 1 |
| Ashley, D; Breazna, A; Cisar, L; Clausen, N; Cruz-Martinez, O; Dorman, A; Elliott, M; English, M; Frappaz, D; Fuster, JL; Geoerger, B; Gesner, L; Grill, J; Hargrave, D; Icher, C; Leblond, P; Perilongo, G; Pietsch, T; Rialland, X | 1 |
| Blaum, M; Galldiks, N; Heinzel, A; Langen, KJ; Mottaghy, FM; Müller, D; Verburg, FA | 1 |
| Fujisaki, H; Hara, J; Okada, K; Osugi, Y; Tanaka, C; Yamasaki, K | 1 |
| Blüml, S; Brown, RJ; Dhall, G; Finlay, JL; Wellner, M; Zaky, W | 1 |
| Aboody, KS; Abramyants, Y; Barish, ME; Brown, CE; Ghoda, LY; Gilchrist, M; Gutova, M; Lacey, SF; Metz, MZ; Najbauer, J; Portnow, J; Potter, PM; Synold, TW; Tirughana, R; Vo, T | 1 |
| Banerjee, A; Boyett, JM; Fahey, F; Fangusaro, J; Fouladi, M; Friedman, HS; Gajjar, A; Gilbertson, RJ; Goldman, S; Gururangan, S; Jakacki, R; Kun, LE; McLendon, RE; Onar-Thomas, A; Packer, RJ; Pollack, IF; Poussaint, TY; Vajapeyam, S; Wu, S | 1 |
| Cloughesy, TF; Dahlbom, M; Huang, SC; Phelps, ME; Schiepers, C; Wardak, M | 1 |
| Chow, L; DeWire, M; Fouladi, M; Goldman, S; Hummel, T; Lane, A; Leach, J; Miles, L; Salloum, R; Stevenson, C; Sutton, M | 1 |
| Bhardwaj, RD; Nakaji, P; Ponce, FA; Rosenfeld, A; Xu, DS | 1 |
| Chen, TC; Golden, EB; Gong, A; Hofman, FM; Howard, A; Jhaveri, N; Louie, SG; Schönthal, AH; Sivakumar, W; Torres, S; Vaikari, VP; Wang, W | 1 |
| Ames, MM; Berg, AK; Buckner, JC; Galanis, E; Jaeckle, KA; Reid, JM | 1 |
| Dalla Pozza, L; Heath, JA; Kalra, M; Kellie, SJ; McCowage, GB; Stevens, MM; Swamy, S | 1 |
| Kanamori, M; Kawashima, R; Mano, Y; Saito, R; Sonoda, Y; Sumiyoshi, A; Tominaga, T; Zhang, R | 1 |
| Baryawno, N; Calero, R; Darabi, A; Dyberg, C; Einvik, C; Johnsen, JI; Kogner, P; Kool, M; Milosevic, J; Sandén, E; Siesjö, P; Sveinbjörnsson, B; Wickström, M | 1 |
| Backus, L; Chow, LM; DeWire, M; Doughman, R; Drissi, R; Fouladi, M; Goldman, S; Grimme, L; Hummel, TR; Kumar, S; Lane, A; Leach, J; Miles, L; Pai, A; Pruitt, D; Salloum, R; Sobo, M; Stevenson, C; Sutton, M | 1 |
| Al-Ghafari, AB; Carrier, DJ; Coyle, B; Hussein, D; Kerr, ID; Punjaruk, W; Storer, LC | 1 |
| André, N; Dory-Lautrec, P; Figarella-Branger, D; Gentet, JC; Heng, MA; Padovani, L; Pasquier, E; Scavarda, D; Verschuur, A | 1 |
| Cha, Y; Choi, B; Choi, SH; Heo, DS; Kim, CY; Kim, DW; Kim, E; Kim, IA; Kim, IH; Kim, JH; Kim, TM; Kim, YJ; Lee, SH; Park, CK | 1 |
| Ahle, G; Antoni, D; Atlani, D; Chaussemy, D; Clavier, JB; Couchot, J; Gaultier, C; Haoming, QC; Jastaniah, Z; Noël, G; Schott, R; Srour, R | 1 |
| Huang, YC; Lee, WH; Liu, SC; Liu, SJ; Su, CH; Tseng, YY; Wang, YC; Yang, ST | 1 |
| Barrie, M; Boucard, C; Campello, C; Chinot, O; Farina, P; Girard, N; Graillon, T; Lehmann, P; Petrirena, G; Tabouret, E | 1 |
| Desjardins, A; Friedman, HS; Reardon, DA; Vredenburgh, JJ | 1 |
| Drappatz, J; Norden, AD; Wen, PY | 1 |
| Anderson, J; Doyle, T; Ellika, S; Jain, R; Mikkelsen, T; Schultz, L; Torcuator, R; Zuniga, RM | 1 |
| Bailey, L; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Marcello, J; Quinn, JA; Reardon, DA; Rich, JN; Sampson, J; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Delattre, JY; Omuro, AM | 1 |
| Ames, MM; Buckner, JC; Felten, SJ; Galanis, E; Jaeckle, KA; Nikcevich, DA; Reid, JM; Santisteban, M; Scheithauer, BW; Wiesenfeld, M; Wu, W | 1 |
| Loutfi, R; Mikkelsen, T; Torcuator, R; Zuniga, R | 1 |
| Cohen, B; Fisher, MJ; Horn, M; Jakacki, R; MacDonald, T; Packer, RJ; Rood, B; Vezina, G | 1 |
| Koga, Y; Kuratsu, J; Kuroda, J; Matsumura, Y; Saito, Y; Yasunaga, M | 1 |
| Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Sampson, JH; Vredenburgh, JJ | 1 |
| Alonso, MM; Bhat, KP; Colman, H; Fueyo, J; Gomez-Manzano, C; Gumin, J; Lang, FF; Lee, OH; Liu, D; Martin, V; Pabbisetty, SK; Xu, J | 1 |
| Colman, H; Conrad, CA; Emmett, MR; He, H; Ji, Y; Kroes, RA; Lang, FF; Marshall, AG; Moskal, JR; Nilsson, CL | 1 |
| Chen, BS; Cui, Y; Jiang, T; Li, SW; Qiu, XG; Ren, H; Zhang, W | 1 |
| Ishikawa, E; Kamiyama, H; Mashiko, R; Matsumura, A; Osuka, S; Takano, S | 1 |
| Anderson, J; Doyle, T; Jain, R; Mikkelsen, T; Schultz, L; Torcuator, R; Zuniga, RM | 1 |
| Baltes, S; Brinker, T; Freund, I; Lewis, AL; Nolte, I | 1 |
| Allen, J; Chacko-Mathew, J; Gardner, S; Harter, D; Karajannis, M; Kunnakkat, S; Narayana, A; Raza, S; Weiner, H; Wisoff, J | 1 |
| Chen, TC; Ghandi, A; Hofman, FM; Liebes, L; Louie, SG; Schönthal, AH; Wang, W | 1 |
| Boyett, JM; Chi, SN; Friedman, HS; Gilbertson, RJ; Gururangan, S; Kun, LE; Onar-Thomas, A; Packer, RJ; Rood, BN; Vajapeyam, S; Young Poussaint, T | 1 |
| Bankiewicz, KS; Berger, MS; Bringas, JR; Dickinson, PJ; Drummond, DC; Forsayeth, J; Higgins, RJ; Kirpotin, DB; Krauze, MT; Larson, RF; LeCouteur, RA; Noble, CO; Park, JW; Yamashita, Y | 1 |
| Chen, J; Lu, Y; Wolff, JE; Xu, T | 1 |
| Chen, C; Damek, D; Fields, EC; Gaspar, LE; Kavanagh, BD; Lillehei, K; Liu, AK; Waziri, A | 1 |
| Goebel, G; Gotwald, T; Güler, O; Hutterer, M; Kostron, H; Nowosielski, M; Recheis, W; Schocke, M; Stockhammer, G; Tinkhauser, G | 1 |
| Dumble, M; Greenberger, LM; Horak, ID; Kraft, P; Mehlig, M; Pastorino, F; Ponzoni, M; Ribatti, D; Sapra, P; Wang, M | 1 |
| Gotwald, T; Hutterer, M; Jacobs, AH; Kostron, H; Muigg, A; Nowosielski, M; Putzer, D; Staffen, W; Stockhammer, G; Tinkhauser, G; Trinka, E; Virgolini, IJ; Waitz, D | 1 |
| Coan, A; Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Peters, KB; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Chan, RT; Fung, CF; Hung, KN; Leung, GK; Ng, GK; Pu, JK | 1 |
| Chen, W; Cloughesy, T; Czernin, J; Dahlbom, M; Huang, SC; Phelps, ME; Satyamurthy, N; Schiepers, C; Wardak, M | 1 |
| Brinker, T; Glage, S; Hedrich, HJ; Held, N; Lewis, AL | 1 |
| Baltes, S; Brinker, T; Geigle, P; Glage, S; Lewis, AL; Mertens, P | 1 |
| Barrie, M; Bequet-Boucard, C; Chinot, O; Colavolpe, C; Figarella-Branger, D; Guedj, E; Mancini, J; Metellus, P; Mundler, O; Tabouret, E | 1 |
| Carrillo, JA; Munoz, CA | 1 |
| Andrés, R; Balañá, C; Benavides, M; de Las Peñas, R; Fernández-Chacón, C; Gallego, O; García-Velasco, A; Gil, MJ; Herrero, A; Martínez-García, M; Mesia, C; Pérez-Martin, X; Peréz-Segura, P; Quintanar, T; Reynés, G | 1 |
| Matsko, MV | 1 |
| Happold, C; Hundsberger, T; Seystahl, K; Weller, M; Wick, A; Wick, W; Wiestler, B | 1 |
| Akman, T; Aktas, B; Alacacioglu, A; Balakan, O; Benekli, M; Buyukberber, S; Coskun, U; Dane, F; Demirci, U; Engin, H; Gunaydin, Y; Harputluoglu, H; Kaplan, MA; Karaca, H; Ozdemir, NY; Sevinc, A; Sonmez, OU; Tonyali, O; Tufan, G; Tugba Unek, I | 1 |
| Bowers, DC; Chintagumpala, MM; Crews, KR; Fouladi, M; Gajjar, A; Heideman, RL; Houghton, PJ; Jones-Wallace, D; Stewart, CF; Thompson, SJ | 1 |
| Kuhn, JG | 1 |
| Baldwin, AS; Cusack, JC; Ewend, MG; Weaver, KD; Yeyeodu, S | 1 |
| Ames, M; Buckner, JC; Cha, S; Erlichman, C; Kaufmann, SH; Miller, LL; O'Fallon, JR; Reid, JM; Schaaf, LJ; Wright, K | 1 |
| Friedman, HS; Houghton, PJ; Keir, ST | 1 |
| Bowers, DC; Chintagumpala, MM; Crews, KR; Gajjar, A; Jones-Wallace, D; Stewart, CF | 1 |
| Cloughesy, TF; Elfring, GL; Filka, E; Friedman, H; Kabbinavar, F; Kuhn, J; Miller, LL; Nelson, G | 1 |
| Friedman, HS; Gilbert, M; Powell, JB; Reardon, DA; Yung, WK | 1 |
| Batchelor, T; Fisher, JD; Gilbert, MR; Grossman, S; Lesser, G; Piantadosi, S; Supko, JG | 1 |
| Buster, WP; Gruber, ML | 1 |
| Batchelor, TT; Carson, KA; Gilbert, MR; Grossman, SA; Lesser, GJ; Mikkelsen, T; Nabors, LB; Phuphanich, S; Supko, JG | 1 |
| Chang, SM; Cloughesy, TF; Fine, HA; Fink, KL; Greenberg, HS; Hess, KR; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, MP; Nicholas, MK; Prados, MD; Robins, HI; Schiff, D; Wen, PY; Yung, WK | 1 |
| Cloughesy, T; Filka, E; Fruehauf, JP; Mehta, R; Parker, RJ | 1 |
| Affronti, ML; Allen, D; Badruddoja, M; Bigner, DD; Bohlin, C; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Silverman, S; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K | 1 |
| Affronti, ML; Allen, D; Bigner, DD; Bohlin, C; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Lentz, C; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Schweitzer, H; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K | 1 |
| Badruddoja, M; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Quinn, JA; Reardon, DA; Rich, JN; Vredenburgh, J | 1 |
| Bowers, DC; Broniscer, A; Chintagumpala, M; Fouladi, M; Gajjar, A; Iacono, L; Krasin, MJ; Stewart, C; Wallace, D | 1 |
| Kamiyama, H; Matsumura, A; Takano, S; Tsuboi, K | 1 |
| Chiocca, EA; Danks, MK; Finkelstein, DM; Hyatt, JL; Leroy, S; Potter, PM; Saeki, Y; Terada, K; Tyminski, E | 1 |
| Badruddoja, M; Burkart, JL; Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, R; Newton, HB; Provenzale, J; Quinn, JA; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, J | 1 |
| Hasegawa, Y; Ishikawa, K; Kajita, Y; Nabeshima, T; Noda, Y; Yoshida, J | 1 |
| Bowers, DC; Broniscer, A; Chintagumpala, M; Fouladi, M; Gajjar, A; Houghton, PJ; Iacono, LC; Kocak, M; Krasin, MJ; Kun, LE; Ledet, D; Merchant, TE; Stewart, CF | 1 |
| Arimochi, H; Morita, K | 1 |
| Hegi, ME; Stupp, R; van den Bent, MJ | 1 |
| Chang, S; Cloughesy, T; Fine, HA; Fink, K; Greenberg, H; Hess, K; Jaeckle, K; Junck, L; Kuhn, J; Lamborn, K; Mehta, M; Nicholas, MK; Prados, MD; Robins, HI; Schiff, D; Wen, PY; Yung, WK | 1 |
| Cloughesy, TF; Lai, A; Mischel, P; Nghiemphu, P; Pope, WB | 1 |
| Barger, G; Brem, H; Brem, S; Fruehauf, JP; Huang, W; Parker, R; Sloan, A | 1 |
| Feun, LG; Heros, D; Herrera, C; Landy, H; Marini, A; Markoe, A; Robles, C; Savaraj, N | 1 |
| Bigner, DD; Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Quinn, JA; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ; Wagner, M | 1 |
| Chen, W; Cloughesy, T; Czernin, J; Delaloye, S; Geist, C; Lai, A; Phelps, ME; Pope, W; Satyamurthy, N; Sayre, J; Silverman, DH | 1 |
| Aldape, KD; Chang, SM; Cloughesy, T; DeAngelis, LM; Fine, H; Fink, KL; Junck, L; Kuhn, J; Lamborn, K; Lieberman, F; Loghin, ME; Metha, M; Prados, MD; Robins, IH; Wen, P; Yung, WK | 1 |
| Blumenthal, DT; Bokstein, F; Shpigel, S | 1 |
| Elinzano, H; Jin, T; Kang, TY; Peereboom, D | 1 |
| Friedman, HS; Malone, S; Petros, WP; Schaaf, LJ; Younis, IR | 1 |
| Fujiwara, T; Matsumoto, Y; Nagao, S | 1 |
| Fujiwara, T; Honjo, Y; Matsumoto, Y; Nagao, S; Sasaoka, N; Tsuchida, T | 2 |
| Bigner, DD; Coggins, CA; Colvin, OM; Elion, GB; Friedman, HS; Hare, CB; Houghton, PJ; Keir, S | 1 |
| Danks, MK; Morton, CL; Naeve, CW; Pawlik, CA; Potter, PM | 1 |
| Burton, E; Prados, M | 1 |
| Ashley, D; Bigner, DD; Cloughsey, T; Cokgor, I; Colvin, OM; Elfring, GL; Friedman, AH; Friedman, HS; Haglund, M; Houghton, PJ; Kerby, T; Lawyer, J; Lovell, S; Malczyn, J; McLendon, RE; Miller, LL; Parry, M; Petros, WP; Provenzale, JM; Rasheed, K; Rich, J; Schaaf, LJ; Stewart, ES | 1 |
| Bom, D; Burke, TG; Curran, DP; Erff, M; Pollack, IF; Strode, JT | 1 |
| Bigner, DD; Castellino, RC; Elion, GB; Friedman, HS; Houghton, PJ; Johnson, SP; Keir, ST | 1 |
| Prados, M | 1 |
| de Bruijn, EA; Dumez, H; Mathijssen, RH; Sparreboom, A; van Oosterom, AT | 1 |
| Beason, R; Bottom, K; Eastwood, J; Friedman, AH; Friedman, HS; Gururangan, S; McLendon, RE; Miller, LL; Tourt-Uhlig, S; Turner, CD; Watral, M | 1 |
| Cloughesy, TF; Elfring, GL; Filka, E; Friedman, H; Kabbinavar, F; Miller, LL; Nelson, G | 1 |
11 review(s) available for irinotecan and Glioma
| Article | Year |
|---|---|
Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Glioma; Humans; Irinotecan; Neoplasm Grading; Neoplasm Recurrence, Local; Prevalence; Survival Rate | 2018 |
Risk of Adverse Vascular Events in Patients with Malignant Glioma Treated with Bevacizumab Plus Irinotecan: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Glioma; Humans; Intracranial Thrombosis; Irinotecan; Risk Factors; Topoisomerase I Inhibitors; Treatment Outcome | 2019 |
Experience with irinotecan for the treatment of malignant glioma.
Topics: Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Glioma; Humans; Irinotecan; Topoisomerase I Inhibitors | 2009 |
Antiangiogenic therapy in malignant gliomas.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Disease-Free Survival; Glioma; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Neoplasm Metastasis; Quality of Life; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Clinical Trials, Phase II as Topic; Disease-Free Survival; Evidence-Based Medicine; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Recurrence; Survival Analysis; Time Factors; Treatment Outcome | 2010 |
Alternative chemotherapeutic agents: nitrosoureas, cisplatin, irinotecan.
Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Cisplatin; Glioma; Humans; Irinotecan; Nitrosourea Compounds | 2012 |
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmustine; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Irinotecan; Neoplasm Recurrence, Local; Temozolomide | 2003 |
Irinotecan: promising activity in the treatment of malignant glioma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Glioma; Humans; Irinotecan; United States | 2003 |
Recent developments in the use of chemotherapy in brain tumours.
Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Dacarbazine; Glioma; Humans; Irinotecan; Temozolomide | 2006 |
New chemotherapy options for the treatment of malignant gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Dacarbazine; Enzyme Inhibitors; Glioma; Humans; Irinotecan; Neovascularization, Pathologic; Oligodendroglioma; Protease Inhibitors; Signal Transduction; Temozolomide; Thalidomide | 1999 |
Temozolomide in combination with other cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carmustine; Central Nervous System Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Implants; Glioma; Humans; Irinotecan; Temozolomide | 2001 |
32 trial(s) available for irinotecan and Glioma
| Article | Year |
|---|---|
A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical Trial/Experimental Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Pilot Projects; Pyridines; Treatment Outcome | 2017 |
A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Irinotecan; Male; Neoplasm Grading; Temozolomide; Treatment Outcome | 2013 |
Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Central Nervous System Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Drug Resistance, Neoplasm; Ependymoma; Female; Glioma; Humans; Irinotecan; Male; Maximum Tolerated Dose; Medulloblastoma; Neoplasm Recurrence, Local; Neoplasms; Rhabdomyosarcoma; Treatment Outcome; Young Adult | 2013 |
Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carbamazepine; Drug Interactions; Enzyme Induction; Female; Glioma; Glucuronates; Humans; Irinotecan; Male; Middle Aged; Phenobarbital; Phenytoin | 2015 |
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2009 |
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cohort Studies; Disease-Free Survival; DNA Topoisomerases, Type I; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Recurrence; Survival Analysis | 2008 |
Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Phytogenic; Area Under Curve; Brain Neoplasms; Camptothecin; Drug Interactions; Female; Glioma; Glucuronides; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local | 2009 |
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Disease-Free Survival; Female; Glioma; Guanine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2009 |
Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Disease-Free Survival; Female; Glioma; Humans; Immunohistochemistry; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Young Adult | 2009 |
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Brain Stem Neoplasms; Camptothecin; Child; Diffusion Magnetic Resonance Imaging; Glioma; Humans; Irinotecan; Neoplasm Recurrence, Local; Phosphorylation; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2010 |
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Cohort Studies; Combined Modality Therapy; Dacarbazine; Dexamethasone; Drug Administration Schedule; Female; Glioma; Glucocorticoids; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prospective Studies; Quinazolines; Radiosurgery; Radiotherapy Dosage; Temozolomide; Tumor Burden; Vincristine; Young Adult | 2012 |
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Glioma; Humans; Indoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sunitinib; Young Adult | 2011 |
Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.
Topics: Adolescent; Adult; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Dose-Response Relationship, Drug; Enzyme Induction; Enzyme Inhibitors; Female; Glioma; Humans; Infusions, Intravenous; Irinotecan; Male; Topoisomerase I Inhibitors | 2002 |
Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.
Topics: Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carbamazepine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Glioma; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Multidrug Resistance-Associated Protein 2; Phenytoin; Probability; Prognosis; Survival Rate; Treatment Outcome | 2002 |
Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Recurrence; Time Factors | 2003 |
Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Dacarbazine; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Treatment Outcome | 2004 |
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.
Topics: Adult; Brain Neoplasms; Camptothecin; Confidence Intervals; Drug Administration Schedule; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate | 2004 |
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Brain Neoplasms; Camptothecin; Dose-Response Relationship, Drug; Female; Glioma; Humans; Irinotecan; Linear Models; Male; Middle Aged; Neoplasm Recurrence, Local; North America; Statistics, Nonparametric | 2004 |
A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Disease Progression; Drug Resistance, Neoplasm; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Predictive Value of Tests; Prospective Studies; Sensitivity and Specificity; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2004 |
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; Confidence Intervals; Female; Glioblastoma; Glioma; Humans; Irinotecan; Male; Middle Aged; Oligodendroglioma | 2004 |
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; Female; Glioblastoma; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma | 2004 |
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Brain Neoplasms; Camptothecin; Celecoxib; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glioma; Humans; Infusions, Intravenous; Irinotecan; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Probability; Pyrazoles; Risk Assessment; Statistics, Nonparametric; Sulfonamides; Survival Analysis; Treatment Outcome | 2005 |
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Infusions, Intravenous; Irinotecan; Male; Temozolomide; Treatment Outcome | 2005 |
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Analysis; Temozolomide; Treatment Outcome | 2005 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Irinotecan; Male; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Disease-Free Survival; Epilepsy; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Treatment Outcome | 2006 |
Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Etoposide; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Teniposide; Tomography, X-Ray Computed | 2007 |
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies | 2007 |
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Drug Administration Schedule; Drug Interactions; Enzyme Induction; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2007 |
Irinotecan therapy in adults with recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Astrocytoma; Brain Neoplasms; Camptothecin; Disease Progression; Female; Glioblastoma; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma | 1999 |
Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Astrocytoma; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Ependymoma; Female; Glioblastoma; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Medulloblastoma; Topoisomerase Inhibitors | 2002 |
Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Topics: Adult; Antineoplastic Agents; Camptothecin; Central Nervous System Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Topoisomerase I Inhibitors | 2002 |
75 other study(ies) available for irinotecan and Glioma
| Article | Year |
|---|---|
Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Glioma; Humans; Irinotecan; Neoplasm Grading; Radiosurgery; Retrospective Studies; Treatment Failure; Treatment Outcome | 2022 |
The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Glioma; Humans; Infant; Irinotecan; Neoplasm Recurrence, Local; Retrospective Studies; Young Adult | 2022 |
Antitumor activity of irinotecan with ellagic acid in C6 glioma cells.
Topics: Animals; Brain Neoplasms; Cadherins; Ellagic Acid; Glioma; Irinotecan; Rats; Vascular Endothelial Growth Factor A | 2022 |
Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Glioblastoma; Glioma; Humans; Irinotecan; Neoplasm Recurrence, Local; Pneumonia, Aspiration; Temozolomide | 2022 |
Enhanced proliferation inhibition and apoptosis in glioma cells elicited by combination of irinotecan and imatinib.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Female; Glioma; Humans; Imatinib Mesylate; Irinotecan; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Rats; Tumor Burden; Tumor Suppressor Protein p53 | 2020 |
Blood-brain barrier disruption and delivery of irinotecan in a rat model using a clinical transcranial MRI-guided focused ultrasound system.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Edema; Brain Neoplasms; Female; Glioma; Irinotecan; Magnetic Resonance Imaging; Male; Microbubbles; Pilot Projects; Prodrugs; Purpura; Random Allocation; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Sonication; Topoisomerase I Inhibitors | 2020 |
Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Child; Child, Preschool; Diffuse Intrinsic Pontine Glioma; Female; Follow-Up Studies; Glioma; Humans; Infant; Irinotecan; Male; Neoplasm Grading; Retrospective Studies; Survival Rate; Temozolomide | 2020 |
Metronomic Maintenance With Weekly Vinblastine After Induction With Bevacizumab-Irinotecan in Children With Low-grade Glioma Prevents Early Relapse.
Topics: Administration, Metronomic; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Child; Child, Preschool; Female; Glioma; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Retrospective Studies; Vinblastine | 2021 |
Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Brain Neoplasms; Cell Line, Tumor; Female; Glioma; Humans; Irinotecan; Mice; Mice, Nude; Nitro Compounds; Temozolomide; Xenograft Model Antitumor Assays | 2021 |
A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Stem Neoplasms; Camptothecin; Cetuximab; Chemoradiotherapy; Child; Child, Preschool; Combined Modality Therapy; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Neoplasm Staging; Prognosis; Survival Rate; Young Adult | 2017 |
Is it time to reconsider the role of irinotecan for the treatment of high-grade gliomas?
Topics: Blood-Brain Barrier; Brain Neoplasms; Glioma; Humans; Irinotecan; Neoplasm Grading; Topoisomerase I Inhibitors; Treatment Outcome | 2018 |
The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Camptothecin; Cost-Benefit Analysis; Decision Trees; Disease-Free Survival; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Monte Carlo Method; Neoplasm Grading; Positron-Emission Tomography; Recurrence; Treatment Outcome; Tyrosine | 2013 |
Treatment of children with diffuse intrinsic pontine gliomas with chemoradiotherapy followed by a combination of temozolomide, irinotecan, and bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Irinotecan; Male; Radiography; Retrospective Studies; Survival Rate; Temozolomide | 2013 |
Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.
Topics: Adenoviridae; Animals; Biotransformation; Brain Neoplasms; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Line, Tumor; Dose-Response Relationship, Drug; Feasibility Studies; Genetic Vectors; Glioma; Humans; Irinotecan; Mice; Mice, Knockout; Mice, SCID; Neural Stem Cells; Rabbits; Time Factors; Tissue Distribution; Topoisomerase I Inhibitors; Transduction, Genetic; Transfection; Xenograft Model Antitumor Assays | 2013 |
Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Female; Follow-Up Studies; Glioma; Humans; Immunoenzyme Techniques; Infant; Irinotecan; Male; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Survival Rate | 2014 |
¹⁸F-FLT and ¹⁸F-FDOPA PET kinetics in recurrent brain tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Camptothecin; Data Interpretation, Statistical; Dideoxynucleosides; Dihydroxyphenylalanine; Female; Glioma; Humans; Irinotecan; Kinetics; Male; Middle Aged; Models, Biological; Positron-Emission Tomography; Radiopharmaceuticals; Recurrence; Tissue Distribution | 2014 |
Patterns of progression in pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma treated with Bevacizumab-based therapy at diagnosis.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Disease Progression; Female; Glioma; Humans; Irinotecan; Male; Neoplasm Grading; Retrospective Studies; Young Adult | 2015 |
Cerebral peduncle tumor ablated by novel 3-mm laser tip.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Camptothecin; Cerebral Peduncle; Child; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Infratentorial Neoplasms; Irinotecan; Laser Therapy; Male; Neoplasms, Multiple Primary; Neurofibromatosis 1; Neuroimaging; Optic Nerve Glioma; Supratentorial Neoplasms; Temozolomide | 2015 |
Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Dendritic Cells; Disease Models, Animal; Drug Delivery Systems; Drug Therapy, Combination; Glioma; Humans; Irinotecan; Mice; Platelet Endothelial Cell Adhesion Molecule-1; Time Factors; Xenograft Model Antitumor Assays | 2015 |
Confirmation of Bevacizumab Activity, and Maintenance of Efficacy in Retreatment After Subsequent Relapse, in Pediatric Low-grade Glioma.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Disease Progression; Female; Follow-Up Studies; Glioma; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retreatment; Retrospective Studies; Salvage Therapy | 2015 |
Convection-enhanced delivery of SN-38-loaded polymeric micelles (NK012) enables consistent distribution of SN-38 and is effective against rodent intracranial brain tumor models.
Topics: Animals; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Convection; Drug Delivery Systems; Gadolinium; Glioma; Humans; Irinotecan; Male; Mice; Micelles; Polymers; Rats; Rats, Inbred F344; Rats, Nude | 2016 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Celecoxib; Cisplatin; Colorectal Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Glucose-6-Phosphate Isomerase; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Immunohistochemistry; Irinotecan; Medulloblastoma; Mice; Neoplasm Transplantation; Neoplasms; Neuroblastoma; Pyrans; Pyrazines; Pyridines; Real-Time Polymerase Chain Reaction; Sulfones; Temozolomide; Triazoles; Tumor Suppressor Proteins; Vincristine; Wnt Proteins; Wnt Signaling Pathway | 2015 |
A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Neoplasm Grading; Pilot Projects; Prognosis; Survival Rate; Temozolomide; Young Adult | 2016 |
Long-term exposure to irinotecan reduces cell migration in glioma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Brain Neoplasms; Camptothecin; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Glioma; Humans; Irinotecan; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay; Wound Healing | 2016 |
Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab-irinotecan in children with low-grade glioma?
Topics: Administration, Metronomic; Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Child; Combined Modality Therapy; Disease Progression; Female; Glioma; Humans; Irinotecan; Maintenance Chemotherapy; Male; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retreatment; Retrospective Studies; Vinblastine | 2016 |
Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Combined Modality Therapy; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Time Factors; Treatment Outcome; Young Adult | 2017 |
Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; Radiosurgery; Radiotherapy, Adjuvant; Re-Irradiation; Retrospective Studies; Temozolomide | 2016 |
Advanced interstitial chemotherapy combined with targeted treatment of malignant glioma in rats by using drug-loaded nanofibrous membranes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bibenzyls; Brain; Brain Neoplasms; Camptothecin; Cisplatin; Disease Models, Animal; Drug Delivery Systems; Ethylnitrosourea; Glioblastoma; Glioma; Humans; Irinotecan; Lactic Acid; Male; Nanofibers; Neurosurgical Procedures; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar; Tumor Burden | 2016 |
Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Glioma; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Retrospective Studies | 2017 |
What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Glioblastoma; Glioma; Humans; Irinotecan | 2008 |
Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Camptothecin; Combined Modality Therapy; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Radiotherapy | 2009 |
Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Glioma; Humans; Infant; Irinotecan; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Prospective Studies; Treatment Outcome | 2009 |
Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Capillary Permeability; Cell Line, Tumor; Glioma; Humans; Irinotecan; Mice; Micelles; Xenograft Model Antitumor Assays | 2009 |
Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Camptothecin; Cell Line, Tumor; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; Inhibitory Concentration 50; Irinotecan; Mitoxantrone; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Receptor, TIE-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transfection; Up-Regulation | 2009 |
Polar lipid remodeling and increased sulfatide expression are associated with the glioma therapeutic candidates, wild type p53 elevation and the topoisomerase-1 inhibitor, irinotecan.
Topics: Animals; Camptothecin; Cell Line, Tumor; Gangliosides; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Glioma; Glycomics; Humans; Irinotecan; Lipids; Mice; Phosphatidylglycerols; Sulfoglycosphingolipids; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2010 |
Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Cell Proliferation; Glioma; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Irinotecan; Male; Mice; Mice, SCID; Neovascularization, Pathologic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome; Withholding Treatment | 2010 |
Doxorubicin and irinotecan drug-eluting beads for treatment of glioma: a pilot study in a rat model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Disease Models, Animal; Doxorubicin; Drug Carriers; Drug Delivery Systems; Female; Glioma; Injections, Intralesional; Irinotecan; Male; Microspheres; Pilot Projects; Rats; Survival Analysis | 2010 |
Bevacizumab in recurrent high-grade pediatric gliomas.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Disease-Free Survival; Female; Glioma; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Young Adult | 2010 |
Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Implants; Glioma; Humans; Irinotecan; Mice; Mice, Nude; Survival Analysis; Tissue Distribution | 2011 |
Canine spontaneous glioma: a translational model system for convection-enhanced delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Convection; Disease Models, Animal; Dogs; Drug Delivery Systems; Glioma; Irinotecan; Liposomes; Magnetic Resonance Imaging; Nanoparticles | 2010 |
ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Diffusion Magnetic Resonance Imaging; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Middle Aged; Prognosis; Recurrence; Retrospective Studies; Treatment Outcome | 2011 |
Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Mice; Mice, Nude; Neoplasm Proteins; Neovascularization, Pathologic; Polyethylene Glycols; Xenograft Model Antitumor Assays | 2011 |
O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Astrocytoma; Bevacizumab; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Disease-Free Survival; Female; Glioma; Humans; Image Processing, Computer-Assisted; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Nervous System Diseases; Positron-Emission Tomography; Postoperative Complications; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Treatment Failure; Tyrosine; Ultrasonography | 2011 |
Using bevacizumab in the fight against malignant glioma: first results in Asian patients.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Asian People; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Glioblastoma; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies | 2011 |
Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Dideoxynucleosides; Discriminant Analysis; Disease-Free Survival; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Prognosis; Radionuclide Imaging | 2011 |
A safety and toxicity assessment of the administration of multiple intracerebral injections of irinotecan or doxorubicin drug-eluting beads.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Cats; Doxorubicin; Female; Glioma; Infusion Pumps, Implantable; Injections, Intraventricular; Irinotecan; Male; Microspheres; Necrosis; Safety; Treatment Outcome | 2011 |
Evaluation of biocompatibility and anti-glioma efficacy of doxorubicin and irinotecan drug-eluting bead suspensions in alginate.
Topics: Alginates; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Doxorubicin; Drug Delivery Systems; Female; Glioma; Glucuronic Acid; Hexuronic Acids; Irinotecan; Male; Materials Testing; Microspheres; Rats; Survival Rate; Suspensions; Tumor Burden | 2012 |
FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Fluorodeoxyglucose F18; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2012 |
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Central Nervous System Neoplasms; Compassionate Use Trials; Dacarbazine; Disease Progression; Glioma; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Treatment Outcome | 2012 |
[Temodal--an alkylating cytostatic agent. Effectiveness in patients with malignant gliomas].
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Doxorubicin; Drug Administration Schedule; Glioma; Humans; Irinotecan; Temozolomide | 2012 |
Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Disease-Free Survival; Drug Therapy, Combination; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2013 |
Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Disease Progression; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Recurrence; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Camptothecin; Carboplatin; Carmustine; Drug Synergism; Genetic Therapy; Glioma; Humans; I-kappa B Proteins; Irinotecan; NF-kappa B; NF-KappaB Inhibitor alpha; Repressor Proteins; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2003 |
Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group.
Topics: Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Glioblastoma; Glioma; Humans; Irinotecan | 2003 |
Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy.
Topics: Adolescent; Adult; Anticonvulsants; Antineoplastic Agents, Phytogenic; Area Under Curve; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; Glioma; Humans; Infusions, Intravenous; Irinotecan; Male; Safety | 2003 |
Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Topics: Adolescent; Adult; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Drug Administration Schedule; Female; Glioma; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Safety; Treatment Outcome | 2003 |
Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Cell Line, Tumor; Endothelial Cells; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glioma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; RNA, Messenger; Transcription Factors; Vascular Endothelial Growth Factor A | 2005 |
Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Brain Neoplasms; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cyclophosphamide; Cytochrome P-450 CYP2B1; Genetic Therapy; Glioma; Herpesvirus 1, Human; Humans; Irinotecan; Prodrugs; Virus Replication | 2005 |
Irinotecan therapy in a 12-year-old girl with recurrent brain stem glioma and without functional polymorphisms in UGT1A1 activity: case report.
Topics: Antineoplastic Agents, Phytogenic; Brain Stem Neoplasms; Camptothecin; Child; Diarrhea; Female; Glioma; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Magnetic Resonance Imaging; Polymorphism, Genetic | 2005 |
High salt culture conditions suppress proliferation of rat C6 glioma cell by arresting cell-cycle progression at S-phase.
Topics: Animals; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media; Early Growth Response Protein 1; Enzyme Inhibitors; Glial Fibrillary Acidic Protein; Glioma; Hypertonic Solutions; Irinotecan; Osmolar Concentration; Rats; Resveratrol; S Phase; Sodium Chloride; Stilbenes | 2005 |
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Camptothecin; Carboplatin; Drug Therapy, Combination; Etoposide; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Vascular Endothelial Growth Factor A | 2006 |
In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Carmustine; Cisplatin; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Glutathione S-Transferase pi; Humans; Immunohistochemistry; Irinotecan; Paclitaxel; Structure-Activity Relationship; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vincristine | 2006 |
Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cell Proliferation; Female; Fluorine Radioisotopes; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiography; Radiopharmaceuticals; Survival Rate; Thymidine | 2007 |
Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Survival Rate | 2008 |
Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cerebral Hemorrhage; Child; Child, Preschool; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Glioma; Humans; Irinotecan; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome | 2008 |
Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Brain Neoplasms; Camptothecin; Enterohepatic Circulation; Female; Glioma; Half-Life; Humans; Irinotecan; Male | 2009 |
Determinants of drug response in camptothecin-11-resistant glioma cell lines.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance; Flow Cytometry; Glioma; Glutathione; Glutathione Transferase; Humans; Irinotecan; Nucleic Acid Conformation; Rats; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1995 |
[Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11].
Topics: Animals; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance; Glioma; Humans; Irinotecan; Rats; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1994 |
Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance; Glioma; Humans; Irinotecan; Rats; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1993 |
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Busulfan; Camptothecin; Carmustine; Child; Cyclophosphamide; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Ependymoma; Female; Glioma; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Topoisomerase I Inhibitors; Transplantation, Heterologous | 1998 |
Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11).
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Base Sequence; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Survival; COS Cells; DNA, Complementary; Glioma; Humans; Irinotecan; Liver; Molecular Sequence Data; Prodrugs; Rabbits; Sequence Alignment; Sequence Homology, Amino Acid; Tumor Cells, Cultured | 1998 |
Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Cell Survival; Genes, p53; Glioma; Humans; Irinotecan; Mice; Mice, Nude; Mutation; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carmustine; Drug Synergism; Drug Therapy, Combination; Female; Glioma; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous | 2000 |
Altered irinotecan metabolism in a patient receiving phenytoin.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Drug Interactions; Glioma; Humans; Irinotecan; Phenytoin; Topoisomerase I Inhibitors | 2002 |